SPOTLIGHT -
Clinical Insights on Evolving Treatment Landscape in Urothelial Carcinoma
Scott T. Tagawa, MD, MS, FACP, FASCO, offers a comprehensive look at the evolving treatment landscape, with a focus on practical considerations and ongoing research.
Urothelial Carcinoma: Safety Profile of Enfortumab Vedotin and Pembrolizumab
An overview of the toxicity profile of enfortumab vedotin and pembrolizumab in patients being treated for urothelial carcinoma.
EV-103: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma
Dr. Tagawa offers his initial impressions on the second patient case and discusses data on enfortumab vedotin plus pembrolizumab for patients with urothelial carcinoma.
Patient Profile 2: A 76-Year-Old With Locally Advanced, Resectable Urothelial Carcinoma
An expert on urothelial carcinoma reviews the case of a 76-year-old patient with advanced, resectable urothelial carcinoma.
Urothelial Carcinoma: Adverse Events From Sacituzumab Govitecan
Scott T. Tagawa, MD, MS, FACP, FASCO, a urothelial carcinoma specialist, discusses adverse events seen in patients receiving sacituzumab govitecan.
Key Treatment Data in Urothelial Carcinoma
A medical oncologist specializing in urothelial carcinoma reviews key data on erdafitinib, enfortumab vedotin, and sacituzumab govitecan.
Overview of Urothelial Carcinoma
An expert on urothelial carcinoma gives an overview of disease risk factors, patient diagnosis, and testing practices.
Patient Profile 1: A 72-Year-Old With Metastatic Urothelial Carcinoma
Scott T. Tagawa, MD, MS, FACP, FASCO, presents the case of 72-year-old patient with metastatic urothelial carcinoma and offers his initial impressions.
